Oncology

Alteogen and Daiichi Sankyo sign license deal for ADC development

Alteogen has entered into an exclusive license agreement with Daiichi Sankyo for the development and commercialisation of a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki), an antibody drug conjugate (ADC).

Plus Therapeutics partners with SpectronRx for CNS therapy development

Plus Therapeutics has entered into a manufacturing services agreement (MSA) with SpectronRx to produce the radiotherapy, Rhenium (186Re) Obisbemeda, for central nervous system (CNS) cancers.

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

NEOGAP and NorthX Biologics partner for cancer cell therapy production

NEOGAP Therapeutics has entered into a partnership with NorthX Biologics, a Swedish contract development and manufacturing organisation (CDMO), to enhance the manufacturing strategies for its personalised cancer cell therapy.

FDA expands approval for Shorla’s JYLAMVO for paediatric patients

The US Food and Drug Administration (FDA) has granted expanded approval to Shorla Oncology’s JYLAMVO (methotrexate) for use in paediatric indications.

Kivu Bioscience secures $92m in Series A funding for ADC development

Kivu Bioscience has completed a $92m Series A funding round, spearheaded by Novo Holdings to propel the development of next-generation antibody-drug conjugates (ADCs).

FDA grants IND clearance for RiboX’s RXRG001

The US Food and Drug Administration (FDA) has granted clearance for RiboX Therapeutics’ investigational new drug (IND) application to commence a Phase I/IIa clinical trial of RXRG001, circular RNA therapy.

Lyell signs agreement to acquire ImmPACT Bio

Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.

TerSera acquires global rights to MacroGenics’ MARGENZA for breast cancer treatment

MacroGenics has granted global rights to the breast cancer drug MARGENZA (margetuximab) to TerSera Therapeutics.